9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Reciprocal regulation of STING and TCR signaling by mTORC1 for T-cell activation and function

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Costimulation of T cells through both TCR and STING induces growth inhibition by partially blocking the mTORC1 signals, and leads to IFN-I production through sustained activation of IRF3 and mTORC1 activation.

          Abstract

          Stimulator of interferon genes (STING) plays a key role in detecting cytosolic DNA and induces type I interferon (IFN-I) responses for host defense against pathogens. Although T cells highly express STING, its physiological role remains unknown. Here, we show that costimulation of T cells with the STING ligand cGAMP and TCR leads to IFN-I production and strongly inhibits T-cell growth. TCR-mediated mTORC1 activation and sustained activation of IRF3 are required for cGAMP-induced IFN-I production, and the mTORC1 activity is partially counteracted by cGAMP, thereby blocking proliferation. This mTORC1 inhibition in response to costimulation depends on IRF3 and IRF7. Effector T cells produce much higher IFN-I levels than innate cells in response to cGAMP. Finally, we demonstrated that STING stimulation in T cells is effective in inducing antitumor responses in vivo. Our studies demonstrate that the outputs of STING and TCR signaling pathways are mutually regulated through mTORC1 to modulate T-cell functions.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found

          STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

          Spontaneous T cell responses against tumors occur frequently and have prognostic value in patients. The mechanism of innate immune sensing of immunogenic tumors leading to adaptive T cell responses remains undefined, although type I interferons (IFNs) are implicated in this process. We found that spontaneous CD8(+) T cell priming against tumors was defective in mice lacking stimulator of interferon genes complex (STING), but not other innate signaling pathways, suggesting involvement of a cytosolic DNA sensing pathway. In vitro, IFN-? production and dendritic cell activation were triggered by tumor-cell-derived DNA, via cyclic-GMP-AMP synthase (cGAS), STING, and interferon regulatory factor 3 (IRF3). In the tumor microenvironment in vivo, tumor cell DNA was detected within host antigen-presenting cells, which correlated with STING pathway activation and IFN-? production. Our results demonstrate that a major mechanism for innate immune sensing of cancer occurs via the host STING pathway, with major implications for cancer immunotherapy. Copyright © 2014 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA.

            The innate immune system recognizes nucleic acids during infection or tissue damage; however, the mechanisms of intracellular recognition of DNA have not been fully elucidated. Here we show that intracellular administration of double-stranded B-form DNA (B-DNA) triggered antiviral responses including production of type I interferons and chemokines independently of Toll-like receptors or the helicase RIG-I. B-DNA activated transcription factor IRF3 and the promoter of the gene encoding interferon-beta through a signaling pathway that required the kinases TBK1 and IKKi, whereas there was substantial activation of transcription factor NF-kappaB independent of both TBK and IKKi. IPS-1, an adaptor molecule linking RIG-I and TBK1, was involved in B-DNA-induced activation of interferon-beta and NF-kappaB. B-DNA signaling by this pathway conferred resistance to viral infection in a way dependent on both TBK1 and IKKi. These results suggest that both TBK1 and IKKi are required for innate immune activation by B-DNA, which might be important in antiviral innate immunity and other DNA-associated immune disorders.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming.

              Naive T cells respond to antigen stimulation by exiting from quiescence and initiating clonal expansion and functional differentiation, but the control mechanism is elusive. Here we describe that Raptor-mTORC1-dependent metabolic reprogramming is a central determinant of this transitional process. Loss of Raptor abrogated T cell priming and T helper 2 (Th2) cell differentiation, although Raptor function is less important for continuous proliferation of actively cycling cells. mTORC1 coordinated multiple metabolic programs in T cells including glycolysis, lipid synthesis, and oxidative phosphorylation to mediate antigen-triggered exit from quiescence. mTORC1 further linked glucose metabolism to the initiation of Th2 cell differentiation by orchestrating cytokine receptor expression and cytokine responsiveness. Activation of Raptor-mTORC1 integrated T cell receptor and CD28 costimulatory signals in antigen-stimulated T cells. Our studies identify a Raptor-mTORC1-dependent pathway linking signal-dependent metabolic reprogramming to quiescence exit, and this in turn coordinates lymphocyte activation and fate decisions in adaptive immunity. Copyright © 2013 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Journal
                Life Sci Alliance
                Life Sci Alliance
                lsa
                lsa
                Life Science Alliance
                Life Science Alliance LLC
                2575-1077
                25 January 2019
                February 2019
                25 January 2019
                : 2
                : 1
                : e201800282
                Affiliations
                [1 ]Laboratory for Cell Signaling, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
                [2 ]Department of Cell Signaling, Institute of Biomedical Sciences, Kansai Medical University, Hirakata, Japan
                [3 ]Laboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
                [4 ]Japan Agency for Medical Research and Development (AMED)-PRIME, Japan Agency for Medical Research and Development, Tokyo, Japan
                [5 ]Graduate School of Medical Life Science, Yokohama City University, Yokohama, Japan
                [6 ]Division of Molecular Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
                [7 ]Division of Innate Immunity, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan
                [8 ]Department of Cell Biology and the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
                [9 ]Division of Physiological Chemistry and Metabolism, Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan
                [10 ]Laboratory of Vaccine Science, World Premier International Research Center Initiative (WPI) Immunology Frontier Research Center, Osaka University, Suita, Japan
                [11 ]Laboratory of Adjuvant Innovation, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
                [12 ]Laboratory of Host Defense, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan
                [13 ]Laboratory for Cell Signaling, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan
                Author notes

                Wakana Kobayashi’s present address is Laboratory for Mucosal Immunity, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

                Takayuki Hoshii's present address is Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, USA and Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, USA

                Author information
                https://orcid.org/0000-0001-9495-3547
                Article
                LSA-2018-00282
                10.26508/lsa.201800282
                6348487
                30683688
                b56be64e-5821-4304-ab3f-d4c4bc130d1a
                © 2019 Imanishi et al.

                This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).

                History
                : 17 December 2018
                : 26 December 2018
                : 7 January 2019
                Funding
                Funded by: Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science KAKENHI;
                Award ID: 16K08852
                Award Recipient :
                Award ID: 24229004
                Award Recipient :
                Categories
                Research Article
                Research Articles
                12

                Comments

                Comment on this article